Table 2. Multivariate Cox proportional hazards analysis for PFS and OS used to adjust risk associated prognostic clinical features.
| All patients (n=224) | PFS | OS | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (continuous) | 0.985 (0.962–1.009) | 0.212 | 0.977 (0.951–1.004) | 0.100 | |
| Initial CA-125 level (U/mL) | |||||
| <35 | 1.000 | - | 1.000 | - | |
| ≥35 | 1.920 (0.983–3.752) | 0.056 | 2.834 (1.055–7.611) | 0.039 | |
| FIGO stage | |||||
| I/II | 1.000 | - | 1.000 | - | |
| III/IV | 2.857 (1.634–4.995) | <0.001 | 4.033 (2.007–8.107) | <0.001 | |
| Grade | |||||
| 1 | 1.000 | - | 1.000 | - | |
| 2 | 1.923 (0.758–4.878) | 0.168 | 1.938 (0.545–6.893) | 0.307 | |
| 3 | 2.233 (0.923–5.405) | 0.075 | 2.530 (0.751–8.526) | 0.134 | |
| Residual disease status after PDS | |||||
| No residual disease | 1.000 | - | 1.000 | - | |
| 0.1–1 cm residual disease | 1.996 (1.161–3.432) | 0.012 | 2.743 (1.361–5.527) | 0.005 | |
| >1 cm residual disease | 2.806 (1.422–5.534) | 0.003 | 3.869 (1.731–8.651) | 0.001 | |
| Arising from endometriosis | |||||
| No | 1.000 | - | 1.000 | - | |
| Yes | 0.675 (0.297–1.532) | 0.347 | 0.483 (0.145–1.613) | 0.237 | |
CA, cancer antigen; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PDS, primary debulking surgery; PFS, progression-free survival.